Skip to main content
Premium Trial:

Request an Annual Quote

Reagent Problem Could Have Affected Rosetta Genomics' Cancer Test Results

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Problems with a reagent may have affected results from about 100 cancer diagnostics tests, Rosetta Genomics reported on Tuesday after the close of the market.

The affected test is the firm's miRview mets — a molecular test for cancer of unknown primary patients that identifies the tissue of origin of metastatic tumors.

In a document filed with the US Securities and Exchange Commission, the Israeli firm disclosed that problems with a reagent used for testing could have affected results for about 100 miRview mets tests performed in the company's CLIA laboratory between August and October.

Rosetta said it has "remediated the problem, has instituted corrective measures to prevent the problem from occurring again and has already begun testing the potentially impacted patient samples."

Retesting of the samples is expected to take up to 10 days.

The company is in the process of notifying clinicians and recommending they not base decisions on the previous test results until they can be confirmed.

It added that it does not expect the issue to result in material liability to the firm.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.